Please assess the completion status of the following clinical trial:

Trial Title: Modulation of the Surgical Inflammatory Response by Etoricoxib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject undergoing elective primary single hip arthroplasty~* Subject diagnosed with Osteoarthritis / arthrosis~* Subject has not taken non-steroidal anti-inflammatory drugs within 4 of their terminal half life times prior to enrollment~* Subject capable of understanding and cooperating with the requirements of the study~Exclusion Criteria:~* Patients with renal insufficiency (serum creatinine \>1.5 mg/dl)~* Recent major trauma or systemic infection (within 3 months)~* Use of corticosteroid medication or chronic opioids (within 3 months)~* Any other condition likely to affect prostaglandin and cytokine levels~* Participation in another clinical study or receipt of an investigational drug within 30 days~* Hypersensitivity to any component of the etoricoxib and/or placebo tablets~* Uncontrolled hypertension defined as systolic blood pressure \>140 mm Hg and diastolic pressure \>90 mm Hg at rest after two repeated measurements~* Congestive heart failure (NYHA II-IV)~* Cerebrovascular disease~* Established ischemic heart disease (including patients who have recently undergone coronary artery bypass graft surgery or angioplasty)~* Patients with any kind or severity of cirrhosis of the liver or cholestasis or elevated liver function enzymes (ALT or AST 3 fold) as a sign of clinical significant liver malfunction (corresponds to any Child-Pugh-Score ≥5)~* Patients who have developed signs of asthma, acute rhinitis, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs)~* Pregnancy and lactation~* Patients with active peptic ulcerations or active gastro-intestinal (GI) bleeding~* Inflammatory bowel disease~* Recent history (within the last year) of alcohol or other substance abuse~* An employee of the sponsor or study site~* Any neurological syndrome or any other condition leading to contra-indication to spinal anesthesia

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A, 1 (Type: EXPERIMENTAL): Study part 1 (n = 8)
- A, 2 (Type: PLACEBO_COMPARATOR): Study part 1 (n = 4)
- B, 1 (Type: EXPERIMENTAL): Study part 2 (n = 20)
- B, 2 (Type: PLACEBO_COMPARATOR): Study part 2 (n = 20)

Based on this trial design, predict the completion outcome and termination type (if applicable).